QLGN - חוב כולל להון Qualigen Corp

This chart of exchange-traded quotes demonstrates the debt-to-equity ratio of Qualigen Therapeutics (QLGN), which currently stands at 0.08. Qualigen Therapeutics (QLGN) develops diagnostic systems and medications for cancer and viruses for medical centers. Geopolitical fragmentation and trade restrictions are hindering overseas product sales, thereby reducing foreign currency revenue. Management is currently cutting ancillary projects to preserve liquidity for the development of its oncology profile.

The stability of the US legal framework minimizes external risks for Qualigen Therapeutics (QLGN), allowing the organization to track the effectiveness of its financial stability management through the total debt-to-equity ratio. This metric compares total liabilities to net assets to determine the proportion of debt financing per unit of equity; an increase in this ratio without scaling revenue signals a critical decline in the business's solvency.